Targeted therapy in early stages of breast cancer can pave the way for a notable higher success rate, shows a study from the University of Bergen, Norway (UiB).
PARP (Poly (ADP-ribose) polymerase) inhibitors represent an established targeted therapy for multiple cancer types, including cancers of the prostate, ovary and rare cases of breast cancer.
PARP inhibitors take advantage of defects in a central mechanism of DNA damage repair, observed in these cancers. While such compounds have been successfully applied in ovarian and prostate cancers, to this end only a small minority of patients with breast cancer (2-3%), harboring germline mutations in the BReast CAncer type-1 and -2 (BRCA1/2) genes have benefitted, and a seminal study conducted 12 years ago reveled no benefit for patients with breast cancer not harboring such mutations.
Now, a national Norwegian study headed by professors Hans Petter Eikesdal, Stian Knappskog and Per Eystein Lønning at University of Bergen and Haukeland University Hospital for the first time reveals benefit of the PARP inhibitor Olaparib in patients with early breast cancer not harboring germline mutations.
Poor prognosis – considerable results
In the PETREMAC study, unselected patients with large (>4 cm diameter) so-called triple negative breast cancers were treated upfront with Olaparib.
Triple negative breast cancers is a breast cancer subgroup often affecting young patients and is a form of breast cancer associated with a poor prognosis.
Among 32 patients treated, 18 (56%) responded with tumor regression on Olaparib monotherapy. Most importantly, 16 out of the 18 responders revealed molecular markers predicting a likely benefit (gene mutations or so-called epigenetic modifications) of genes involved in the process of DNA repair contrasting only 4 out of 14 non-responders.
These findings allow identification of individual tumors likely to benefit from PARP inhibition. Five patients harbored germline mutations (i.e. patients that may potentially be treated with a PARP inhibitor prior to this study).
However, among patients not harboring such germline mutations (i.e. patients that would normally be excluded from PARP inhibitor therapy), 14/26 patients (54%) responded to therapy. Moreover, among these 14 patients, 12 could be identified upfront as likely responders based on analyzing their tumor tissue for mutations / epimutations affecting DNA repair.
Improved personalized treatment
In conclusion, the study challenges the previous dogma that PARP inhibition may not work for patients not harboring germline mutations. Most importantly, the authors found a strong correlation between response to therapy and molecular markers easily detectable in the tumor tissue.
“While the results need confirmation in independent studies, our results point toward improved personalized treatment for many patients diagnosed with triple negative breast cancer”, says professor Lønning.
Finally, the study illuminates a concept gaining increasing support in oncology: While previous studies revealed no benefit from PARP inhibition in late-stage breast cancer, this study demonstrates a therapy which was ineffective in late cancer may potentially be of great benefit in the early setting.
Featured image: Outline of study arms of the neoadjuvant PETREMAC trial © Eikesdal et al.
Reference: H.P. Eikesdal, S. Yndestad et al., “Olaparib monotherapy as primary treatment in unselected triple negative breast cancer”, Annals of Oncology, Volume 32, Issue 2, pp. 240-249, 2021. DOI: https://doi.org/10.1016/j.annonc.2020.11.009
Provided by University of Bergen